Clinical Analysis of Successful IVF Cases in China: Key Factors Influencing Live Birth and Decision-Making Reference

▎Clinical Scenario — A 38-year-old woman, AMH 1.1 ng/mL, FSH 9.6 IU/L, ultrasound shows antral follicle count of 4 on the left and 3 on the right, with a history of bilateral tubal patency issues. Her husband's semen concentration and motility are normal, but DNA fragmentation is 25%. She asks: "Given my situation, what is the likelihood of IVF success in China? Which factors are most critical?"

1. What Constitutes a True "Successful IVF Case"

In assisted reproductive medicine, the definition of a successful case is a live birth, meaning at least one healthy infant is born at term or near term. Clinical pregnancy (gestational sac seen on ultrasound) or ongoing pregnancy (after 12 weeks of gestation) are intermediate endpoints and cannot be considered final markers of success. The reason is that approximately 15%–25% of clinical pregnancies result in spontaneous miscarriage in the first trimester, with over 80% of these related to embryonic chromosomal aneuploidy. Therefore, when evaluating a fertility center's success rate, the live birth rate per single transfer or cumulative live birth rate should be used, not the "clinical pregnancy rate" or "HCG positive rate."

2. Why Some Patients Succeed While Others Experience Repeated Failure

From clinical observation, the differences between success and failure primarily stem from four levels:

• Oocyte Quality and Embryo Euploidy — This is the most core factor. Increasing female age directly leads to a higher rate of oocyte aneuploidy. The embryo euploidy rate is about 50%–60% for women under 35, dropping to 20%–30% for those over 40.
• Endometrial Receptivity — Even with a euploid embryo, insufficient endometrial thickness (<7 mm), abnormal endometrial pattern (e.g., loss of triple-line sign), or a displaced window of implantation (asynchrony between the endometrium's receptive period for embryo implantation and embryo development) can lead to transfer failure.
• Uterine and Pelvic Environment — Intrauterine adhesions, chronic endometritis, endometrial polyps, and hydrosalpinx reflux can all interfere with implantation.
• Laboratory and Clinical Quality Control — Culture media batches, incubator stability, embryologist experience, and subtle differences in transfer technique can all affect the final outcome.

Successful cases are often the result of all four levels being simultaneously in a "favorable range." Conversely, a significant defect in any one link can lead to failure.

3. The Clinical Decision-Making Logic for Assessing Success Probability

In the consultation room, a doctor does not simply give a "can succeed" or "cannot succeed" judgment based solely on an AMH report or age. The actual assessment process includes the following steps:

1. Baseline Reserve Assessment: Measure FSH, LH, E2, and AMH on days 2–4 of the menstrual cycle, along with a transvaginal ultrasound to count antral follicles (AFC). AMH <1.0 ng/mL or AFC <5 indicates poor ovarian response, necessitating protocols like Progestin-Primed Ovarian Stimulation (PPOS) or mild stimulation.
2. Uterine Cavity Assessment: 3D ultrasound to rule out endometrial polyps, submucosal fibroids, or intrauterine adhesions; if suspicious, perform hysteroscopy and endometrial microbiome testing.
3. Estimated Embryo Yield: Based on previous stimulation history or AMH levels, predict the number of oocytes retrieved, maturation rate, and blastocyst formation rate. For example, a 38-year-old patient with AMH 1.1 ng/mL is expected to yield about 5–9 oocytes, with a blastocyst formation rate of approximately 35%–50%.
4. Genetic Risk Assessment: Recommend PGT-A (preimplantation genetic testing for aneuploidy) for patients with recurrent implantation failure or advanced maternal age to reduce miscarriage due to embryonic abnormalities.
5. Comprehensive Judgment: After synthesizing the above information, the doctor will explain the "expected live birth probability range" to the patient, rather than a single number. For example, "Based on your age and reserve, the cumulative live birth rate per oocyte retrieval is approximately 15%–25%. It is advisable to consider accumulating 2–3 cycles."

4. Differences in Success Characteristics Among Patients of Different Ages

It should be noted that the above data are compiled from annual quality control reports of multiple reproductive medicine centers in China. Due to differences in patient selection criteria, there may be a fluctuation of 5–10 percentage points between centers. However, age as an independent influencing factor ranks first in weight across all studies.

5. Where Do Differences in Success Rates Between Fertility Centers Come From?

Many patients ask: "Why do some fertility centers report high live birth rates while others are average?" In fact, differences in success rates mainly originate from three aspects:

• Patient Selection Criteria: Some centers primarily treat "young, normal ovarian reserve, male factor" patients, naturally leading to higher success rates. Centers that treat a large number of advanced-age, premature ovarian failure, or recurrent failure patients will have their overall live birth rate lowered. Therefore, directly comparing crude live birth rates is meaningless; one should look at "live birth rates for different age subgroups."
• Laboratory Quality Control Level: Blastocyst formation rate, good-quality blastocyst rate, and freeze-thaw survival rate are core indicators of a laboratory. Top domestic centers can achieve blastocyst formation rates of 55%–65%, while some centers may only have 35%–45%. This directly affects the number of transferable embryos.
• Differences in Transfer Strategy: Centers adopting a freeze-all embryo strategy typically have live birth rates 5–8 percentage points higher than centers primarily using fresh transfers. This is because the endometrium is more receptive in frozen-thawed cycles, and it avoids the impact of Ovarian Hyperstimulation Syndrome (OHSS) on the endometrium.

6. Details Most Easily Overlooked That Affect Success

Based on a review of 2000+ cycles over the past 5 years, the following details are often underestimated by patients:

• Vitamin D Levels — Serum 25-hydroxyvitamin D <30 ng/mL is associated with decreased endometrial receptivity and failed embryo implantation. It is recommended to supplement to normal range 2 months before starting the cycle.
• Thyroid Function — Even TSH >2.5 mIU/L within the "normal range" increases the risk of early miscarriage. The target level should be controlled between 1.5–2.5 mIU/L.
• Male DNA Fragmentation Index (DFI) — Even if routine semen analysis is normal, DFI >30% significantly reduces blastocyst formation and live birth rates. It is recommended to complete DFI testing before ovulation induction, and consider testicular sperm aspiration if necessary.
• Timing of Endometrial Receptivity Testing — For patients with recurrent implantation failure, an endometrial receptivity assay (ERA) should be performed in the cycle prior to transfer to determine if the window of implantation is displaced. About 25%–30% of patients have a window of implantation different from the conventional time.

7. Common Cognitive Misconceptions That Patients Easily Fall Into

In outpatient clinics, the following misconceptions frequently appear and directly affect patients' treatment decisions:

• "I'm young, so I'm sure to succeed." — While overall success rates are high for those under 30, if there is diminished ovarian reserve (e.g., AMH <1.0), endometriosis, or severe male factor infertility, the live birth rate may still be lower than the average for that age group. Individualized assessment is more important than age alone.
• "Lying in bed for 14 days after transfer will ensure implantation." — Prolonged bed rest does not increase implantation rates and may actually increase the risk of thrombosis. Normal activity, avoiding strenuous exercise, is sufficient.
• "If this cycle fails, switching to another hospital will guarantee success next time." — Frequently changing centers can lead to repeated testing and disrupted cycle continuity. Unless there is a clear quality control issue at the original center, it is recommended to complete at least 2–3 oocyte retrieval cycles at the same center before evaluating whether to transfer.
• "Using the most expensive ovulation induction protocol will yield the best embryos." — The choice of ovulation induction protocol should be based on ovarian reserve characteristics and previous response, not price. For patients with Polycystic Ovary Syndrome (PCOS), a mild stimulation protocol may yield a higher rate of euploid embryos compared to a strong stimulation protocol.

8. Timeline for a Complete Treatment Cycle

From the initial consultation to confirmation of live birth, a standard IVF cycle typically takes 3–5 months. The specific milestones are as follows:

If PGT-A is planned or if a cycle is cancelled and needs to be restarted, the overall timeline may extend to 6–8 months. Patients are advised to adjust their work and life schedules accordingly.

9. Typical Scenario Analysis: From Test Report to Successful Live Birth

Returning to the 38-year-old patient with AMH 1.1 ng/mL mentioned at the beginning. After a complete evaluation, the clinical team formulated the following strategy:

• Ovulation Induction Protocol: PPOS protocol (Progestin-Primed Ovarian Stimulation) was used, yielding 7 oocytes, 6 mature, 5 fertilized, and 3 blastocysts formed (2 x 4BB, 1 x 3BC).
• Genetic Screening: Of the 3 blastocysts, 2 were euploid (normal PGT-A result), and 1 was mosaic.
• Endometrial Preparation: Hormone replacement cycle, endometrial thickness 8.2 mm, clear triple-line sign, pattern grade B.
• Transfer Strategy: A single euploid blastocyst (4BB) was selected for frozen-thawed transfer.
• Outcome: Blood HCG was 386 IU/L 12 days post-transfer, a single fetal heartbeat was seen on ultrasound at 6 weeks, and a male infant weighing 3100 g with Apgar scores of 9–10 was delivered vaginally at 38+3 weeks.

This case is not a "miracle" but a result achieved as expected through matching clinical decisions with patient conditions. The key supporting factors for its success include: despite low AMH, usable euploid embryos were available; good endometrial receptivity; and the transfer of a single, genetically screened blastocyst, avoiding the risks of multiple pregnancy and miscarriage.

10. Questions Most Frequently Asked by Patients